Difference between revisions of "Panitumumab (Vectibix)"
Jump to navigation
Jump to search
m (Text replace - "package insert<ref name="insert"></ref>." to "prescribing information.<ref name="insert"></ref>") |
m (updated reference) |
||
| Line 1: | Line 1: | ||
| + | Also known as ABX-EGF. | ||
| + | |||
==General information== | ==General information== | ||
| − | Class/mechanism: EGFR antagonist; recombinant human IgG2 kappa monoclonal antibody that binds to EGFR (human epidermal growth factor receptor), competitively inhibiting binding of epidermal growth factor (EGF). EGFR is overexpressed in certain cancers, such as colon & rectal cancer, and plays a role in the signal transduction pathways that lead to transcription of genes that promote cell growth, survival, and motility. Blocking EGFR in a population overexpressing EGFR has been observed to inhibit cell growth and induce apoptosis.<ref name="insert">[http://pi.amgen.com/united_states/vectibix/vectibix_pi.pdf Panitumumab (Vectibix) package insert]</ref><ref>[ | + | Class/mechanism: EGFR antagonist; recombinant human IgG2 kappa monoclonal antibody that binds to EGFR (human epidermal growth factor receptor), competitively inhibiting binding of epidermal growth factor (EGF). EGFR is overexpressed in certain cancers, such as colon & rectal cancer, and plays a role in the signal transduction pathways that lead to transcription of genes that promote cell growth, survival, and motility. Blocking EGFR in a population overexpressing EGFR has been observed to inhibit cell growth and induce apoptosis.<ref name="insert">[http://pi.amgen.com/united_states/vectibix/vectibix_pi.pdf Panitumumab (Vectibix) package insert]</ref><ref>[[Media:Panitumumab.pdf | Panitumumab (Vectibix) package insert (locally hosted backup)]]</ref><ref>[http://www.vectibix.com/ Vectibix manufacturer's website]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
| + | |||
| + | ==Diseases for which it is used== | ||
| + | *[[Colon cancer]] | ||
==Patient drug information== | ==Patient drug information== | ||
*[http://chemocare.com/bio/panitumumab.asp Panitumumab (Vectibix) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/panitumumab.asp Panitumumab (Vectibix) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/bio/panitumumab.asp Panitumumab (Vectibix) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/panitumumab.asp Panitumumab (Vectibix) patient drug information (Chemocare)]</ref> | ||
| + | *Brief patient counseling information can be found on page 15 of the [http://pi.amgen.com/united_states/vectibix/vectibix_pi.pdf#page=15 Panitumumab (Vectibix) package insert]<ref name="insert"></ref> | ||
*[http://www.uptodate.com/contents/panitumumab-patient-drug-information Panitumumab (Vectibix) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/panitumumab-patient-drug-information Panitumumab (Vectibix) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/panitumumab-patient-drug-information Panitumumab (Vectibix) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/panitumumab-patient-drug-information Panitumumab (Vectibix) patient drug information (UpToDate)]</ref> | ||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 03:20, 15 September 2012
Also known as ABX-EGF.
General information
Class/mechanism: EGFR antagonist; recombinant human IgG2 kappa monoclonal antibody that binds to EGFR (human epidermal growth factor receptor), competitively inhibiting binding of epidermal growth factor (EGF). EGFR is overexpressed in certain cancers, such as colon & rectal cancer, and plays a role in the signal transduction pathways that lead to transcription of genes that promote cell growth, survival, and motility. Blocking EGFR in a population overexpressing EGFR has been observed to inhibit cell growth and induce apoptosis.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Panitumumab (Vectibix) patient drug information (Chemocare)[4]
- Brief patient counseling information can be found on page 15 of the Panitumumab (Vectibix) package insert[1]
- Panitumumab (Vectibix) patient drug information (UpToDate)[5]